On this basis, we initiated a phase 2 clinical trial (EudraCT # 2019-001988-75; ClinicalTrials.gov identifier: NCT04224441), adding CPZ to standard GBM treatment (TMZ + radiation) in patients with a tumor with a hypomethylated MGMT gene promoter, which is characterized by resistance to TMZ and a worse prognosis. The gene discussed is MGMT; the disease is glioblastoma.